{"id":"NCT03494504","sponsor":"Aldeyra Therapeutics, Inc.","briefTitle":"ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis","officialTitle":"A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions (0.25% and 0.5%) Compared to Vehicle in the Conjunctival Allergen Challenge (Ora-CACÂ®) Model of Acute Allergic Conjunctivitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-30","primaryCompletion":"2018-11-05","completion":"2018-11-05","firstPosted":"2018-04-11","resultsPosted":"2025-02-11","lastUpdate":"2025-02-11"},"enrollment":318,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Reproxalap Ophthalmic Solution (0.25%)","otherNames":[]},{"type":"DRUG","name":"Reproxalap Ophthalmic Solution (0.5%)","otherNames":[]},{"type":"DRUG","name":"Vehicle Ophthalmic Solution","otherNames":[]}],"arms":[{"label":"Reproxalap Ophthalmic Solution (0.25%)","type":"EXPERIMENTAL"},{"label":"Reproxalap Ophthalmic Solution (0.5%)","type":"EXPERIMENTAL"},{"label":"Vehicle Ophthalmic Solution","type":"PLACEBO_COMPARATOR"}],"summary":"A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis","primaryOutcome":{"measure":"Subject-reported Ocular Itching Score","timeFrame":"Efficacy was assessed after a single dose; baseline was assessed approximately two weeks before dosing.","effectByArm":[{"arm":"Reproxalap Ophthalmic Solution (0.25%)","deltaMin":52.003,"sd":3.3053},{"arm":"Reproxalap Ophthalmic Solution (0.5%)","deltaMin":60.04,"sd":3.4552},{"arm":"Vehicle Ophthalmic Solution","deltaMin":74.657,"sd":3.3076}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":109},"commonTop":["General disorders and administration site conditions"]}}